tiprankstipranks
Advertisement
Advertisement
RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access
PremiumCompany AnnouncementsRemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access
1M ago
RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer
Premium
Company Announcements
RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer
2M ago
RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results
2M ago
RemeGen Signs Up to US$5.6 Billion Global Licensing Deal with AbbVie for Cancer Drug RC148
PremiumCompany AnnouncementsRemeGen Signs Up to US$5.6 Billion Global Licensing Deal with AbbVie for Cancer Drug RC148
4M ago
RemeGen Co., Ltd. Announces A Share Repurchase Plan to Boost Employee Incentives
Premium
Company Announcements
RemeGen Co., Ltd. Announces A Share Repurchase Plan to Boost Employee Incentives
5M ago
RemeGen Co., Ltd. Approves Key Resolutions at 2025 EGM
Premium
Company Announcements
RemeGen Co., Ltd. Approves Key Resolutions at 2025 EGM
5M ago
RemeGen Co., Ltd. Schedules Board Meeting to Review Q3 Results
PremiumCompany AnnouncementsRemeGen Co., Ltd. Schedules Board Meeting to Review Q3 Results
7M ago
RemeGen Co., Ltd. Engages in Strategic Cash Management with SPDB Wealth Products
Premium
Company Announcements
RemeGen Co., Ltd. Engages in Strategic Cash Management with SPDB Wealth Products
7M ago
RemeGen Co., Ltd. Engages in Wealth Management Product Purchase
Premium
Company Announcements
RemeGen Co., Ltd. Engages in Wealth Management Product Purchase
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100